FDA Gives Okay to DNA Test for Common Hereditary Cancers

On Sept. 29, the U.S. Food and Drug Administration (FDA) granted de novo marketing authorization for Invitae’s Common Hereditary Cancers Panel, a blood test that evaluates DNA to identify variants in 47 genes associated with an increased cancer risk. The test is the first of its kind to be given FDA marketing authorization.